Загрузка...
Phase 2 trial of Sorafenib in Children and Young Adults with Refractory Solid Tumors: A Report from the Children’s Oncology Group
BACKGROUND: Sorafenib is an oral small molecule inhibitor of multiple kinases controlling tumor growth and angiogenesis. The purpose of this phase 2 study was to determine the response rate of sorafenib and gain further information on the associated toxicities, pharmacokinetics, and pharmacodynamics...
Сохранить в:
| Опубликовано в: : | Pediatr Blood Cancer |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4515771/ https://ncbi.nlm.nih.gov/pubmed/26207356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25548 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|